Publications by authors named "Line Abildgaard Ryberg"
Article Synopsis
- The evolution of SARS-CoV-2 has resulted in several variants of concern (VOCs), especially omicron sub-lineages, which display resistance to neutralizing antibodies from past infections or vaccinations.
- In this study, researchers created various mutant viruses with spike protein changes from VOCs like omicron JN.1, and analyzed their resistance to neutralization using plasma from recovered and vaccinated individuals.
- Findings revealed that while specific changes in the spike receptor binding domain contribute to resistance, alterations outside this region are also important; additionally, some omicron variants showed a reduced reliance on the ACE2 receptor for viral entry but maintained increased binding affinity for it.
Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development. However, the risk of resistance development threatens the future efficacy of such direct-acting antivirals. To gain knowledge on viral correlates of resistance to Mpro inhibitors, we selected resistant SARS-CoV-2 under treatment with the nirmatrelvir-related protease inhibitor boceprevir.
View Article and Find Full Text PDFThe oral protease inhibitor nirmatrelvir is of key importance for prevention of severe coronavirus disease 2019 (COVID-19). To facilitate resistance monitoring, we studied severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) escape from nirmatrelvir in cell culture. Resistant variants harbored combinations of substitutions in the SARS-CoV-2 main protease (Mpro).
View Article and Find Full Text PDF